SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings beat, supported by growth in Dupixent and Eylea HD, sparked a sharp share-price jump and fresh highs. Traders are largely celebrating the results and breakout, while debating whether the rally can hold or will pull back.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A strong third-quarter earnings beat and raised full-year revenue outlook, driven by demand for Mounjaro and Zepbound, are fueling LLYs rally and bullish talk about its highs and analyst upgrades. Some traders question the valuation and point to lower profit guidance from acquisition-related charges and weaker-than-expected Foundayo sales.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileyes quarterly results beat expectations and slightly raised its outlook, but shares sold off to a new 52-week low as traders questioned the modest growth, the contribution of an Israeli R&D grant to profitability, and the companys ability to win advanced-driving programs amid competition. The reaction is split between bearish short sellers and investors who view the cash position and autonomous-driving opportunities as support for a recovery.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTXs breakout to a fresh 52-week high is drawing attention ahead of its expected Q3 report, with traders focused on BRIUMVIs sales momentum and guidance, plus the coming subcutaneous data. Buyout and short-squeeze theories are adding to bullish sentiment, though those remain speculation and some traders caution that strong results may already be priced in.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Reports of abrupt layoffs in India and the Philippines, attributed to a scaled-down business assignment, have fueled concern that Innodata may have lost or reduced a major client project. Traders disagree over whether the cuts signal weaker demand or a shift toward leaner operations; the company has not clarified the reason, and investors are looking to earnings for more detail.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial reached its 80th overall-survival event, triggering database lock, unblinding and final analysis ahead of expected topline results this quarter for its GPS treatment in AML. Traders are split between bullish expectations for a survival benefit and skepticism about the still-unknown results, with debate over trial design and dosing alongside concern about the share-price decline after the milestone.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

Alnylam Pharmaceuticals Inc

Alnylam is under pressure after its post-earnings selloff, as traders focus on slower Amvuttra demand growth and guidance reductions. Some see the drop as an overreaction with shares near multi-year support, while others remain concerned about commercial momentum and further downside.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

A sharp selloff in gold has pushed GLD to a 52-week low, with traders citing expectations for a more hawkish Fed and possible forced liquidation as pressure on the metal. The move has prompted debate over golds safe-haven role: bears see more downside, while some investors are treating the drop as a buying opportunity.

Hyperliquid (HYPE) is a cryptocurrency and operates on the Hyperliquid platform. Hyperliquid has a current supply of 950,404,567.00039228 with 253,519,445.96520927 in circulation. The last known price of Hyperliquid is 87.80548337 USD and is down -2.36 over the last 24 hours. It is currently trading on 350 active market(s) with $1,945,115,780.75 traded over the last 24 hours. More information can be found at https://hyperliquid.xyz/.

Hype

HYPEs rally toward record highs and the $100 level dominates discussion, with bullish traders pointing to fee-funded buybacks and growing institutional access to Hyperliquids perpetual markets. Others warn that the move may be overextended, citing volatility, pullbacks, and short-term resistance.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

MAGS is drawing attention amid volatile Mag Seven trading and rotation between mega-cap tech and semiconductors. Bears point to heavy AI spending and pressure on cash flow as risks, while dip buyers see the pullback as a potential support test rather than a break in the longer-term trend.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
